Why the study?
Patients undergoing PCI in vessels with moderate-to-severe tortuosity face higher risk of adverse outcomes, but data are scarce with newer-generation stents.
Does a bioresorbable-polymer sirolimus-eluting stent reduce target lesion failure compared to a durable-polymer everolimus-eluting stent in patients undergoing PCI with moderate-to-severe coronary artery tortuosity?
Does a bioresorbable-polymer sirolimus-eluting stent reduce target lesion failure compared to a durable-polymer everolimus-eluting stent in patients undergoing PCI with moderate-to-severe coronary artery tortuosity?
In patients with moderate-to-severe coronary tortuosity undergoing PCI, the use of bioresorbable-polymer sirolimus-eluting stents significantly reduces target lesion failure at 3 years compared to durable-polymer everolimus-eluting stents.
Answers are grounded in this paper and cite their sources.
Supports BP-SES over DP-EES to reduce TLF in tortuous vessels; extends stent comparisons to this high-risk anatomy.
INTRODUCTION AND OBJECTIVES: Patients undergoing percutaneous coronary intervention in vessels with moderate-to-severe tortuosity are at higher risk of adverse outcomes, but data are scarce in the era of newer-generation stents. We compared outcomes following percutaneous coronary intervention in vessels with moderate-to-severe tortuosity using a bioresorbable-polymer sirolimus-eluting stent (BP-SES) vs a durable-polymer everolimus-eluting stent (DP-EES). METHODS: A total of 2350 patients from the BIOFLOW II, IV, and V randomized trials were stratified into 2 groups based on target-vessel tortuosity: none-to-mild and moderate-to-severe. The primary endpoints included target lesion failure (TLF)-a composite of cardiac death, target-vessel myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (TLR)-and probable/definite stent thrombosis at 3 years. RESULTS: Patients with moderate-to-severe tortuosity (n=903) had more comorbidities than those with none-to-mild tortuosity (n=1447). Rates of TLF (P=.354), cardiac death (P=.690), TLR (P=.447), and stent thrombosis (P=.084) were similar between the 2 groups, whereas TV-MI occurred more frequently in the moderate-to-severe tortuosity group (P=.031). However, on multivariate analysis, moderate-to-severe tortuosity was not an independent predictor of TV-MI (adjusted HR, 1.06; 95% CI, 0.72-1.55; P=.772). Among patients with moderate-to-severe tortuosity, the use of BP-SES was associated with significantly lower rates of TLF compared with the DP-EES (7.8% vs 13.4%; HR, 0.57; 95% CI, 0.37-0.87; P=.009), driven by reductions in TV-MI (5.0% vs 9.2%; HR, 0.54; 95% CI, 0.32-0.90; P=.018) and TLR (2.7% vs 6.1%; HR, 0.45; 95% CI, 0.23-0.90; P=.021). CONCLUSIONS: This pooled analysis of the randomized BIOFLOW trials demonstrates that patients with none-to-mild and moderate-to-severe tortuosity have comparable long-term adverse event rates. However, the use of BP-SES in patients with moderate-to-severe tortuosity may help mitigate potential ischemic risks. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov NCT01356888, NCT01939249, NCT02389946.
No takes yet. Share an insight, caveat, or question.
Mankerious et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: